GlassScriptPhysician profile
John Z Nan
NPI 1013336643
$12,049.64
in general payments reported to CMS, 2019-2025
18 companies · $7,509 in 2025
The $7,509 reported for 2025 was more than what 87% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $565 · 2023: $2,911 · 2024: $276 · 2025: $7,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,890 · Food and Beverage: $2,034 · Travel and Lodging: $1,771 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,890.00 |
| Food and Beverage | $2,033.60 |
| Travel and Lodging | $1,771.38 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $8,689.32 | 2022-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic, INC. | $2,016.81 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $388.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $212.11 | 2023-2025 | |
| Chiesi USA, INC. | $132.02 | 2021 | |
| Cardiovascular Systems INC. | $124.34 | 2021 | |
| Abiomed | $89.46 | 2023 | Impella |
| Cvrx, INC. | $81.47 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $80.27 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $53.18 | 2023-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $52.64 | 2023-2024 | Xarelto |
| Cardiva Medical, INC. | $24.53 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Asahi Intecc USA, INC. | $22.89 | 2023 | Asahi Ptca Guide Wire |
| Regeneron Healthcare Solutions, INC. | $21.76 | 2025 | Evkeeza |
| Scpharmaceuticals INC. | $16.69 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.34 | 2024 | Verquvo |
| Biotronik INC. | $14.95 | 2025 | |
| Amgen INC. | $13.80 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.